Literature DB >> 16955185

Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up.

Willem M Star1, Albert J van't Veen, Dominic J Robinson, Kai Munte, Ellen R M de Haas, Henricus J C M Sterenborg.   

Abstract

Photodynamic therapy (PDT) of superficial basal cell carcinoma using topical 5-aminolaevulinic acid (ALA) and 75-100 J/cm2 light dose yields unsatisfactory long-term results. In several animal models, illumination with two light fractions approximately 2 h apart was considerably more effective than single illumination, suggesting the need for a pilot clinical study. Fifteen patients with a total of 86 primary superficial basal cell carcinomas, received topical ALA and were illuminated 4 and 6 h later, both with 45 J/cm2 laser light (633+/-1 nm). Fluorescence spectra were measured before and immediately after each illumination. At a mean follow-up of 59 months (range 44-82), 67 lesions could be evaluated, 56 of which showed a complete response (84%). Cosmesis was good/excellent in 88% of the complete response group and fair in 12%. There was no correlation between protoporphyrin fluorescence and response, but a significant correlation between the percentage of fluorescence left after photobleaching by the first illumination and the amount of protoporphyrin re-synthesized 2 h later. In conclusion, the long-term complete remission rate of fractionated ALA-mediated PDT of superficial basal cell carcinoma as reported here is significantly better than after PDT with single illumination previously reported by others, but equal to studies using single illumination with a much higher light fluence. Further improvement may be possible by reducing the fluence of the first fraction, with constant total fluence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955185     DOI: 10.2340/00015555-0129

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  6 in total

Review 1.  Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Authors:  Harry Quon; Craig E Grossman; Jarod C Finlay; Timothy C Zhu; Clarice S Clemmens; Kelly M Malloy; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-06       Impact factor: 3.631

2.  A comparative study on the enhancement efficacy of specific and non-specific iron chelators for protoporphyrin IX production and photosensitization in HaCat cells.

Authors:  Yumin Xia; Yingying Huang; Longde Lin; Xiaoming Liu; Shan Jiang; Layuan Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

3.  Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.

Authors:  Henriëtte S de Bruijn; Sander Brooks; Angélique van der Ploeg-van den Heuvel; Timo L M Ten Hagen; Ellen R M de Haas; Dominic J Robinson
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

4.  Six years of experience in photodynamic therapy for Basal cell carcinoma: results and fluorescence diagnosis from 191 lesions.

Authors:  M Fernández-Guarino; A Harto; B Pérez-García; A Royuela; P Jaén
Journal:  J Skin Cancer       Date:  2014-09-14

5.  Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.

Authors:  Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; Stephen Chad Kanick; Scott C Davis; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Br J Cancer       Date:  2016-08-30       Impact factor: 7.640

6.  An in vitro study of the effect of 5-ALA-mediated photodynamic therapy on oral squamous cell carcinoma.

Authors:  Ying Ma; Shujuan Qu; Liangpeng Xu; Hongbo Lu; Baoguo Li
Journal:  BMC Oral Health       Date:  2020-09-16       Impact factor: 2.757

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.